Frits van Rhee
University of Arkansas · University of Arkansas for Medical Science-Myeloma Institute · UAMS
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
17
all conditions, ClinicalTrials.gov
NIH grants tied to them
2
NIH RePORTER
Trial papers
0
PubMed author-name match
Trials
Studies that name Frits van Rhee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:31 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04396496 · Treatment of POEMS Syndrome With DaratumumabUniversity of Arkansas · completed · POEMS Syndrome · principal investigator
- Ph2NCT03003728 · 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)University of Arkansas · withdrawn · Multiple Myeloma · principal investigator
- Ph2NCT03004287 · 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyUniversity of Arkansas · active not recruiting · Multiple Myeloma · principal investigator
- Ph2NCT02192775 · UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles VirusUniversity of Arkansas · completed · Multiple Myeloma · principal investigator
- Ph2NCT02128230 · UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionUniversity of Arkansas · terminated · Multiple Myeloma · principal investigator
- Ph2NCT01884688 · UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple MyelomaUniversity of Arkansas · completed · Asymptomatic Multiple Myeloma · principal investigator
- Ph2NCT01313897 · UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple MyelomaUniversity of Arkansas · completed · Multiple Myeloma · principal investigator
- Ph2NCT00869232 · UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionUniversity of Arkansas · active not recruiting · Multiple Myeloma · principal investigator
- Ph2NCT00577512 · 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACEUniversity of Arkansas · completed · Multiple Myeloma · principal investigator
- Ph1NCT00578045 · UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological MalignanciesUniversity of Arkansas · withdrawn · Multiple Myeloma · principal investigator
- Ph3NCT00574080 · UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and ThalidomideUniversity of Arkansas · terminated · Multiple Myeloma · principal investigator
- Ph1NCT00425347 · Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple MyelomaFacet Biotech · completed · Multiple Myeloma · principal investigator
- Ph2NCT00113932 · UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple MyelomaUniversity of Arkansas · completed · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT00113919 · UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma PatientsUniversity of Arkansas · terminated · Multiple Myeloma · principal investigator
- Ph2/Ph3NCT00090493 · Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple MyelomaUniversity of Arkansas · completed · Multiple Myeloma · principal investigator
- Ph1NCT00089453 · Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell TransplantUniversity of Arkansas · completed · Multiple Myeloma · principal investigator
- Ph3NCT00083915 · DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE ConsolidationUniversity of Arkansas · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Developmental TherapeuticsP01CA055819 · NCI · UNIV OF ARKANSAS FOR MED SCIS · fiscal years 2009 to 2013 · $300,399 awarded in 2013Same name and institution; not confirmed by an ID
- Potentiating Natural Killer Cell Anti-Myeloma EffectsR01CA134522 · NCI · UNIV OF ARKANSAS FOR MED SCIS · fiscal years 2008 to 2012 · $291,849 awarded in 2012Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.